ABVC BioPharma
ABVC
8 hedge funds and large institutions have $333K invested in ABVC BioPharma in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.
159% more capital invested
Capital invested by funds: $129K → $333K (+$204K)
0.98% more ownership
Funds ownership: 1.43% → 2.41% (+0.98%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
+$231K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.75K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.27K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$42K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$31.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CIC
1
Chase Investment Counsel
Charlottesville,
Virginia
| $233K | +$231K | +178,377 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $61.5K | +$25.5K | +19,700 | +72% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $28.8K | +$3.27K | +2,520 | +13% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $5.82K | +$5.75K | +4,440 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.3K | +$2.52K | +1,942 | +336% |
|
|
SAG
6
Spotlight Asset Group
Oakbrook Terrace,
Illinois
| $131 | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $63 | +$36 | +28 | +140% |
|
|
8
Renaissance Technologies
New York
| – | -$42K | -36,100 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$31.5K | -27,158 | Closed |
|
ABVC Hedge Fund Activity: Q1 2024 in Review
8 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2024, worth a combined $333K — up 159% from $129K a quarter earlier.
Fund positioning in ABVC was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 0 trimmed.
The largest buyer was Chase Investment Counsel, opening a new position worth an estimated $231K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $42K sold.
- 8 institutional investors held ABVC BioPharma (ABVC) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $333K of ABVC BioPharma stock for Q1 2024, up 159% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q1 2024 was Chase Investment Counsel, an estimated $231K added.
- The largest ABVC BioPharma seller in Q1 2024 was Renaissance Technologies, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2024.